Silexion Therapeutics Corp

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

SLXN$0.11-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows (unaudited)

	Six months ended June 30		Three months ended June 30
	2026	2025	2026	2025
U.S. dollars in thousands · U.S. dollars in thousands
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$(6,284)	$(4,238)	$(3,551)	$(2,503)
Adjustments required to reconcile loss to net cash used in operating activities:
Depreciation	5	7	3	3
Share-based compensation expenses	542	58	197	37
Non-cash financial expenses	(131)	310	(135)	229
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses	(802)	(717)	157	(205)
Increase in other current assets	(62)	(1)	(15)	(5)
Increase (decrease) in trade payable	393	(237)	268	(30)
Net change in operating lease	(11)	1	(7)	2
Increase (decrease) in employee related obligations	(251)	(14)	68	4
Increase (decrease) in other account payable	30	(129)	90	(39)
Net cash used in operating activities	(6,571)	(4,960)	(2,925)	(2,507)
CASH FLOWS FROM INVESTING ACTIVITIES-
Investment in long-term deposits	(1)	-	(1)	-
Purchase of property and equipment	-	(7)	-	(1)
Net cash used in investing activities	(1)	(7)	(1)	(1)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of Ordinary Shares under the At-the-Market Sales Agreement	2,071	-	1,985	-
Payment and prepayment of issuance costs related to At-the-Market Sales Agreement	(121)	-	(118)	-
Proceeds from issuance of ordinary shares upon January 2025 Offering	-	5,000	-	-
Issuance costs related to January 2025 Offering	-	(745)	-	(95)
Proceeds from exercise of warrants upon January 2025 Offering	-	864	-	-
Proceeds from issuance of ordinary shares upon January 2025 and May 2026 Inducement Offer	998	3,276	998	-
Issuance costs related to warrants inducement transaction	(125)	(462)	(125)	(100)
Payment of Underwriters Promissory Note	-	(696)	-	-
Net cash provided by (used in) financing activities	2,823	7,237	2,740	(195)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(3,749)	2,270	(186)	(2,703)
EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(6)	4	8	14
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD	6,075	1,270	2,498	6,233
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD	$2,320	$3,544	$2,320	$3,544

F - 8

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six months ended June 30 · Three months ended June 30
2026 · 2025 · 2026 · 2025
U.S. dollars in thousands · U.S. dollars in thousands
Appendix A – RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:
Cash and cash equivalents		2,229		3,466		2,229		3,466
Restricted cash		91		78		91		78
TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS		$2,320		$3,544		$2,320		$3,544
Appendix B - SUPPLEMENTARY INFORMATION:
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Prepaid issuance expenses utilized, in respect of At-the-Market Sales Agreement		$60	$	-		$53	$	-
Accrued and unpaid issuance expenses in respect of May 2026 Inducement Offer		$44	$	-		$44	$	-
Conversion of Promissory Note to ordinary shares		$414		$356		$414	$	-
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid	$	-		$13	$	-	$	-
Interest received		$46		$46		$14		$44

F - 9

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.